Literature DB >> 10160095

Timing and timeliness in medical care evaluation.

B S Bloom1, A M Fendrick.   

Abstract

Mesh:

Year:  1996        PMID: 10160095     DOI: 10.2165/00019053-199609030-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  13 in total

1.  The historical development of clinical therapeutic trials.

Authors:  J P BULL
Journal:  J Chronic Dis       Date:  1959-09

2.  Issues in mandatory economic assessment of pharmaceuticals.

Authors:  B S Bloom
Journal:  Health Aff (Millwood)       Date:  1992       Impact factor: 6.301

Review 3.  A comparative review of pharmacoeconomic guidelines.

Authors:  P Jacobs; J Bachynsky; J F Baladi
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

4.  Abruptly changing patterns of diffusion and use of extracorporeal shock-wave renal lithotripsy.

Authors:  B S Bloom; A L Hillman; J S Schwartz
Journal:  Am J Kidney Dis       Date:  1991-07       Impact factor: 8.860

5.  The tension between cost containment and the underutilization of effective health services.

Authors:  B S Bloom; A M Fendrick
Journal:  Int J Technol Assess Health Care       Date:  1996       Impact factor: 2.188

6.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

Authors:  K F Schulz; I Chalmers; R J Hayes; D G Altman
Journal:  JAMA       Date:  1995-02-01       Impact factor: 56.272

7.  Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease.

Authors:  A L Hillman; B S Bloom; A M Fendrick; J S Schwartz
Journal:  Arch Intern Med       Date:  1992-07

8.  Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.

Authors:  A G Mulley; M D Silverstein; J L Dienstag
Journal:  N Engl J Med       Date:  1982-09-09       Impact factor: 91.245

9.  A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.

Authors:  B S Bloom; A L Hillman; A M Fendrick; J S Schwartz
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

10.  Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.

Authors:  K A Schulman; H A Glick; H Rubin; J M Eisenberg
Journal:  JAMA       Date:  1991-12-25       Impact factor: 56.272

View more
  1 in total

Review 1.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.